...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Updates

"....But in order for Zenith to achieve the milestones you point out it needs cash....The Zenith financials paint a very dire picture...."

That's less true than it was at any point in the last two years when a financing was their only option. Now the possibilities are a financing or a license deal or an IPO.

Share
New Message
Please login to post a reply